摘要
Graves眼病(GO)为Graves病的甲状腺外表现,是由细胞免疫介导的复杂的自身免疫性疾病,眼眶成纤维细胞和眼眶脂肪细胞是免疫反应的靶细胞,促甲状腺激素受体和胰岛素样生长因子-1是关键的自身靶抗原。除吸烟、放射性碘治疗后等危险因素外,高胆固醇血症被发现为GO新的危险因素。糖皮质激素至今在中重度活动性GO的治疗中有不可撼动的地位,但部分患者经治疗后并没有反应,或出现了复发。生物靶向制剂、细胞因子抑制剂以及具有抗炎作用的他汀类药物等已逐步研究并应用于GO的临床治疗。文章对GO主要发病机制及目前中重度活动性GO药物治疗的新进展进行综述。
Graves ophthalmopathy(GO)is an extrathyroidal manifestation of Graves’disease,mainly a complex autoimmune disease mediated by cellular immunity.Orbital fibroblasts and adipocytes are target cells for immune response,while Thyroid stimulating hormone receptor and insulin-like growth factor-1 are key autoantigens.In addition to smoking,post radiation iodine therapy,and other risk factors,hypercholesterolemia has been identified as a new risk factor for GO.Corticosteroids have an unshakable position in the treatment of moderate to severe active GO,but some patients do not respond after treatment or experience recurrence.It is necessary to seek new drugs.Bio-targeted agents,cytokine inhibitors,and statins with anti-inflammatory effects have gradually been studied and applied in the clinical treatment of GO.This review mainly introduces the main pathogenesis of GO and the new progress in drug therapy for moderate to severe active GO.
作者
王璇璐(综述)
彭年春
胡颖(审校)
Wang Xuanlu;Peng Nianchun;Hu Ying(Department of Endocrine and Metabolic Diseases,Affiliated Hospital of Guizhou Medical University,Guizhou Province,Guiyang 550004,China)
出处
《疑难病杂志》
CAS
2024年第5期635-640,共6页
Chinese Journal of Difficult and Complicated Cases
基金
2022年度贵州省卫生健康委科学技术基金项目(gzwkj-2022-001)
2021年贵州医科大学附属医院博士科研启动基金项目(gyfybskt-2021-11)。
